| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03731117 Details | 2020-12-16 Interventional | 4 | 11 | Furosemide Acute Kidney In… Kidney Tubular … Necrosis | Study end date exceeded and insufficient number of subjects needed for analysis. 11 patients
included / 70 theoretical patients - | |||
| NCT02943473 Details | 2020-12-16 Interventional | 2 | 9 | Ibrutinib Multiple Myelom… Neoplasms, Plas… Smoldering Mult… High Risk Smold… | Poor accrual and risk/benefit ratio. - | |||
| NCT02489097 Details | 2020-12-16 Interventional | 4 | [3 Refs] | 140 | Nitrous Oxide Cognition Disor… Cognitive Dysfu… Neurocognitive … Anesthesia Delirium, Demen… | Interim analysis results showed futility - | ||
| NCT00765856 Details | 2020-12-16 Interventional | 3 | 27 | Oxymorphone Chronic Pain | Terminated new protocol developed which incorporated Pharmacokinetics - | |||
| NCT00161330 Details | 2020-12-14 Interventional | 3 | - | Amoxicillin Ceftriaxone Clavulanic Acid Clavulanic Acid… Communicable Di… Infections Urinary Tract I… | - - | |||
| NCT04664803 Details | 2020-12-11 Interventional | 4 | 284 | Cefdinir Cefetamet Sinusitis Acute Sinusitis | - - | |||
| NCT04433546 Details | 2020-12-11 Interventional | 2 | 54 | VIP-ELP fusion … Acute Lung Inju… COVID-19 Cardiovascular … Clinical Deteri… Cytokine Releas… Heart Failure Inflammation Pneumonia Pulmonary Edema Respiratory Dis… Respiratory Dis… Respiratory Ins… Syndrome Acute Respirato… COVID 19 Cardiac Complic… Cardiac Dysfunc… Cardiac Event Cardiac Failure Cardiac Infarct Coronavirus Cytokine Storm Hypoxemic Respi… Hypoxic Respira… Pulmonary Infla… Respiratory Com… Respiratory Fai… SARS-CoV-2 | Company no longer pursing indication - | |||
| NCT04329923 Details | 2020-12-10 Interventional | 2 | [1 Refs] | 173 | Hydroxychloroqu… COVID-19 | Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
pre-specificied futility analysis at planned second interim analysis Sub-study 1 was terminated early after the first interim analysis due to slow accrual Sub-study 2 was terminated early after the first 7 patients based on the recommendation of UPenn research oversight committees Sub-study 3 was terminated early due to meeting futility criteria on a pre-specified second interim analysis | ||
| NCT03468075 Details | 2020-12-10 Interventional | 2 | 10 | Ascorbic Acid Gemcitabine Osteosarcoma Sarcoma Bone Sarcoma Metastatic Bone… Soft Tissue Sar… Unresectable So… | Stopping rules met Study terminated early. Ten patients were enrolled in the first stage, and per protocol the study was terminated following interim analysis when 1 or fewer participants had a tumor response. | |||
| NCT01402401 2011-002570-23 Details | 2020-12-10 Interventional | 2 | 21 | Trastuzumab Stomach Neoplas… Advanced Gastri… | - - | |||
| NCT00794417 Details | 2020-12-10 Interventional | 1/2 | [2 Refs] | 60 | Aflibercept Pemetrexed Carcinoma Carcinoma, Non-… Lung Neoplasms Advanced Carcin… Non-small Cell … | - - | ||
| NCT01278849 2009-016471-30 Details | 2020-12-09 Interventional | 1 | 5 | Vadimezan Histologically-… | - - | |||
| NCT01278758 2009-017159-88 Details | 2020-12-09 Interventional | 1 | 7 | Vadimezan Neoplasm Metast… Renal Insuffici… Metastatic Canc… | - - | |||
| NCT01240642 2009-011142-26 Details | 2020-12-09 Interventional | 1 | 27 | Vadimezan Neoplasm Metast… Neoplasms Neoplasms, Seco… Renal Insuffici… Metastatic Canc… Metastatic Canc… | - - | |||
| NCT00730522 Details | 2020-12-09 Interventional | 2 | 55 | Vigabatrin Methamphetamine… | To conserve remaining capital, Sponsor decided to terminate the study early. Study terminated early due to other failed indication for product and only limited data collected without complete analysis. CPP-109 stopped all development in substance dependent indications. Therefore, not able to summarize most data, as not available. | |||
| NCT04410354 Details | 2020-12-08 Interventional | 2 | 44 | Remdesivir COVID-19 | Failure to meet primary endpoint - | |||
| NCT02651272 Details | 2020-12-08 Interventional | 2 | 4 | Macitentan Anemia, Sickle … Hypertension Hypertension, P… Pulmonary Hyper… Sickle Cell Dis… | Unable to enroll IRB approved sample of participants. Early termination as unable to enroll participants. | |||
| NCT01841502 Details | 2020-12-08 Interventional | 2 | 3 | Paroxetine Hepatitis Hepatitis C Depression Hepatitis C Inf… | Telaprevir will not be used in NL, no more inclusions are expected. - | |||
| NCT01300611 NCT01302678 Details | 2020-12-08 Interventional | 1 | - | Angiotensin I (… Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Myelodysplastic… Precursor Cell … Acute Lymphobla… Acute Myelogeno… Chronic Lymphoc… Chronic Myelocy… Double Cord Blo… Hodgkins Lympho… Myelodysplastic… Myelofibrosis Non Hodgkins Ly… | - - | |||
| NCT01121120 Details | 2020-12-08 Interventional | 2 | 75 | Angiotensin I (… Hodgkin Disease Lymphoma Lymphoma, Non-H… Multiple Myelom… Neoplasms, Plas… | - - |